Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).
Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer (Abstract S2-05).
Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment (Plenary Lecture 1).
